Tenax Therapeutics Inc. – Material Contracts Watch

from 10-Q 28 pages Certain Information Identified With the Mark “[***]” Has Been Excluded From This Exhibit Because Such Information Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed Supply Agreement This Supply Agreement (Hereinafter the/This “Agreement”) Has Been Made and Executed as of This 29th Day of June, 2026 (Hereinafter the “Effective Date”) by and Between Orion Corporation a Company Organised Under the Laws of Finland, (Business Identity Code Fi 19992126), With Its Principal Offices at Orionintie 1, 02200 Espoo, Finland, (Hereinafter “Orion”) and Tenax Therapeutics, Inc. a Company Organized Under the Laws of Delaware Business Identity Code Ein Number 26-2593535 With Its Principal Offices at 101 Glen Lennox Drive, Suite 300, Chapel Hill, Nc, 27517, USA

from 8-K 4 pages Sixth Amendment to the License Agreement of September 20, 2013

from 8-K 7 pages Third Amendment to Executive Employment Agreement

from 8-K 6 pages First Amendment to Executive Employment Agreement

from 8-K 7 pages First Amendment to Executive Employment Agreement

from 8-K 6 pages Tenax Therapeutics, Inc. Notice of Inducement Restricted Stock Unit Grant

from 8-K 14 pages Executive Employment Agreement

from 8-K 3 pages Second Amendment to Executive Employment Agreement

from 8-K 7 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Such Excluded Information Has Been Marked With “[***].” Fifth Amendment to the License Agreement of September 20, 2013

from 10-K 10 pages Tenax Therapeutics, Inc. Notice of Inducement Stock Option Grant

from 10-K 4 pages Fourth Amendment to the License Agreement of September 20, 2013

from 8-K 17 pages Registration Rights Agreement

from 8-K 30 pages Securities Purchase Agreement

from 8-K 1 page Amendment No. 2 to the Tenax Therapeutics, Inc. 2022 Stock Incentive Plan

from 8-K 24 pages Registration Rights Agreement

from 8-K 40 pages Securities Purchase Agreement

from 8-K 4 pages Amendment to Executive Employment Agreement

from 8-K 1 page Amendment No. 1 to the Tenax Therapeutics, Inc. 2022 Stock Incentive Plan

from 8-K 5 pages Certain Information Identified With the Mark “[***]” Has Been Excluded From This Exhibit Because Such Information Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed Third Amendment to the License Agreement of September 20, 2013

from 8-K 30 pages Securities Purchase Agreement